Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population

• Published in: PloS one Vol. 10; no. 6; p. e0124653
• Main Authors: Shah, Nigam H, LePendu, Paea, Bauer-Mehren, Anna, Ghebremariam, Yohannes T, Iyer, Srinivasan V, Marcus, Jake, Nead, Kevin T, Cooke, John P, Leeper, Nicholas J
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 10.06.2015; Public Library of Science (PLoS)
• Subjects: Adult; Algorithms; Aspirin; Cardiovascular diseases; Clopidogrel; Data mining; Data processing; Gastroesophageal reflux; Health risks; Heart attack; Heart attacks; Humans; Hypotheses; Infarction; Informatics; Middle Aged; Mortality; Myocardial infarction; Myocardial Infarction - chemically induced; Pharmacology; Pharmacovigilance; Product safety; Prospective Studies; Proton pump inhibitors; Proton Pump Inhibitors - adverse effects; Risk; Risk Factors; Studies; Survival analysis; Thrombosis; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Vascular surgery; Young Adult; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0124653

Proton pump inhibitors (PPIs) have been associated with adverse clinical outcomes amongst clopidogrel users after an acute coronary syndrome. Recent pre-clinical results suggest that this risk might extend to subjects without any prior history of cardiovascular disease. We explore this potential risk in the general population via data-mining approaches. Using a novel approach for mining clinical data for pharmacovigilance, we queried over 16 million clinical documents on 2.9 million individuals to examine whether PPI usage was associated with cardiovascular risk in the general population. In multiple data sources, we found gastroesophageal reflux disease (GERD) patients exposed to PPIs to have a 1.16 fold increased association (95% CI 1.09-1.24) with myocardial infarction (MI). Survival analysis in a prospective cohort found a two-fold (HR = 2.00; 95% CI 1.07-3.78; P = 0.031) increase in association with cardiovascular mortality. We found that this association exists regardless of clopidogrel use. We also found that H2 blockers, an alternate treatment for GERD, were not associated with increased cardiovascular risk; had they been in place, such pharmacovigilance algorithms could have flagged this risk as early as the year 2000. Consistent with our pre-clinical findings that PPIs may adversely impact vascular function, our data-mining study supports the association of PPI exposure with risk for MI in the general population. These data provide an example of how a combination of experimental studies and data-mining approaches can be applied to prioritize drug safety signals for further investigation.